Latest News Archive

Please select Category, Year, and then Month to display items

Afromontane Research Unit gets R8,4 million injection

11 January 2021 | Story André Damons | Photo Supplied

The Afromontane Research Unit (ARU), the flagship research group of the University of the Free State (UFS) Qwaqwa Campus, has recently been granted R8,4 million to establish a Risk and Vulnerability Science Centre programme.

The Risk and Vulnerability Science Centre (RVSC) programme was established by the Department of Science and Innovation (DSI) as part of the Global Change Research Plan for South Africa and is funded by the DSI through the National Research Foundation (NRF). The RVSC will focus on the need to generate and disseminate knowledge about risk and vulnerability on global change challenges faced by local policy makers/ governance structures and communities in South Africa.

Invited to participate

Dr Ralph Clark, Director of the ARU, says the UFS, together with the University of Zululand and the Sol Plaatje University, has been invited to participate in Phase 2 of the RVSC programme. Dr Clark was approached by the DSI (on referral from the South African Environmental Observation Network – SAEON) in February 2020 regarding the potential for establishing a RVSC at the UFS Qwaqwa campus.

Subsequent interactions were held between the UFS and DSI, and in March 2020, the UFS formally accepted the DSI invitation. It has since been agreed that the RVSC: UFS will be hosted as a RVSC under the ARU umbrella, with dedicated personnel embedded at the UFS in this regard (internal processes and reporting) but reporting directly to the NRF regarding the RVSC.

Interest and support welcomed

Dr Clark welcomed this interest and support from the DSI-NRF, saying that the funds will further assist the UFS in growing its excellent and growing research portfolio and building more research capacity on this traditionally undergraduate-focused campus. “The RVSC will contribute to much-needed solutions in an area marked by major sustainability challenges and will assist in moving Phuthaditjhaba away from its negative apartheid history towards becoming a sustainable African mountain city,” says Dr Clark.

News Archive

Haemophilia home infusion workshop

2017-12-17

Parents receive training for homecare of their children with haemophilia.
Photo Supplied

Caregivers for haemophilia patients, and patients themselves from around the Free State and Northern Cape attended a home infusion workshop held by the Clinical Skills unit in the Faculty of Health Sciences in July 2017. “It felt liberating and I feel confident to give the factor to my son correctly,” said Amanda Chaba-Okeke, the mother of a young patient, at the workshop. Her son, also at the workshop, agreed. “It felt lovely and good to learn how to administer factor VIII.”

Clinical skills to empower parents and communities
There were two concurrent sessions: one attended by doctors from the Haemophilia Treatment Centre, and the other attended by community members including factor VIII and XI recipients, caregivers and parents. The doctors’ meeting was shown informative videos and demonstrations on how to administer the newly devised factor VII and XI kit, and discussed the pressing need for trained nurses at local clinics. Dr Jaco Joubert, a haematologist, made an educational presentation to the community members.

The South African Haemophilia Foundation was represented by Mahlomola Sewolane, who gave a brief talk about the role of the organisation in relation to the condition. Meanwhile, procedural training in the simulation laboratory involved doctors and nurses helping participants to learn the procedures by using mannequins and even some volunteers from among the patients.

A medical condition causing serious complications
Haemophilia is a medical condition in which the ability of the blood to clot is severely impaired, even from a slight injury. The condition is typically caused by a hereditary lack of a coagulation factor, most often factor VIII. Usually patients must go through replacement therapy in which concentrates of clotting factor VIII (for haemophilia A) or clotting factor IX (for haemophilia B) are slowly dripped or injected into the vein, to help replace the clotting factor that is missing or low. Patients have to receive this treatment in hospital.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept